Saturday 17 October 2026
Export LSDIF’s income statement to Excel — free account
Lucy Scientific Discovery Inc.
LSDIF Healthcare Drug Manufacturers Specialty & Generic
Operating cash flow growth for three consecutive years.
0.00
0.00
NaN
Follow LSDIF
| Jun '23 | Jun '22 | Jun '21 | Jun '20 | |
|---|---|---|---|---|
P/E ratio |
0.00 | — | — | — |
Altman Z-Score |
(6.99) | — | — | — |
P/S ratio |
0.00 | — | — | — |
P/FCF ratio |
0.00 | — | — | — |
Altman Z″-Score (non-manufacturers) |
(18.94) | — | — | — |
P/Operating CF |
(7.85) | — | — | — |
P/B ratio |
3.12 | — | — | — |
Price to Tangible BV |
4.57 | — | — | — |
EV/Sales |
0.00 | — | — | — |
EV/EBITDA |
0.00 | — | — | — |
EV/Operating CF |
(3.36) | — | — | — |
EV/FCF |
(3.39) | — | — | — |
Quick Ratio |
0.74 | 0.01 | 0.05 | 0.02 |
Current Ratio |
1.41 | 0.33 | 0.07 | 0.03 |
Net Debt/EBITDA |
0.29 | (0.86) | (0.73) | (0.43) |
Debt/Assets |
0.00% | 65.38% | 39.45% | 1,063.32% |
Debt/Equity |
0.00 | (0.63) | (0.34) | (0.29) |
Asset Turnover |
0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.47 | 0.41 | 0.31 | 0.17 |
Capex/Depreciation |
(2.48) | (3.31) | — | — |
Interest Coverage |
(2.97) | (1.68) | (2.27) | (33.31) |
| 18,140.26% | 105.19% | 88.39% | 0.00% | |
| (134.06%) | (114.98%) | (166.57%) | 0.00% | |
ROIC |
(121.55%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(478.88%) | 190.88% | 131.27% | 82.72% |
Average Days of Receivables |
17,926.71 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | — | — | 0.00% |
Selling, General and Administrative Expense of Revenue |
82,398.57% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.17 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
13,587.14% | 0.00% | — | — |
Graham Net Nets |
(0.02) | — | — | — |
Graham Number |
0.00 | — | — | — |
Earnings Yield |
(61.49%) | — | — | — |
Free Cash Flow Yield |
(28.98%) | — | — | — |
Revenue per Share |
0.01 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(3.36) | (2.81) | (0.09) | (0.03) |
Capex per Share |
(0.21) | (0.04) | 0.00 | 0.00 |
Free Cash Flow per Share |
(3.57) | (2.85) | (0.09) | (0.03) |
Cash per Share |
1.32 | 0.06 | 0.02 | 0.00 |
Shareholders Equity per Share |
3.68 | (5.55) | (0.40) | (0.27) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.68 | (5.55) | (0.40) | (0.27) |
Free Cash Flow |
(4.53) | (2.45) | (1.48) | (0.50) |
Working Capital |
1.11 | (3.91) | (4.44) | (3.63) |
Capital Expenditures |
(0.27) | (0.03) | — | — |
Net Current Asset Value |
(0.28) | (7.51) | (11.58) | (4.36) |
EV/EBIT |
0.00 | — | — | — |
Capex to Sales |
37.99 | 0.00 | — | — |
Price to Operating Income |
0.00 | — | — | — |
| Other line items | ||||
Depreciation/Fixed assets |
0.14 | 0.01 | 0.00 | — |
Cash ROIC |
(71.34%) | 144.58% | 37.88% | 16.54% |
Accounts Receivable Turnover |
0.04 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
0.00 | — | — | — |
Inventory Turnover |
0.00 | — | — | — |
Average Days of Payables |
104,722.56 | 0.00 | — | — |
Days of Inventory on Hand |
0.00 | — | — | — |
Average Receivables |
0.18 | 0.01 | 0.01 | — |
Average Payables |
2.05 | — | — | — |
Average Assets |
6.71 | 5.09 | 2.84 | — |
Average Common Equity |
(0.05) | (5.57) | (5.35) | — |
Columns are period end dates